Showing results (161-170 of 316) with videos related to

Sort By:
Pageof 32
Scientific Reports|August 5, 2020
Quantitative T2 MRI is predictive of neurodegeneration following organophosphate exposure in a rat modelKevin Lee, Sara Bohnert, Matthew Bouchard, et al.
Pain|June 10, 2008
Regional brain activation in conscious, nonrestrained rats in response to noxious visceral stimulationZhuo Wang, Sylvie Bradesi, Jean-Michel I Maarek, et al.
Heliyon|November 20, 2018
Conversion of adult human fibroblasts into neural precursor cells using chemically modified mRNABronwen Connor, Erin Firmin, Amy McCaughey-Chapman, et al.
International Journal of Environmental Research and Public Health|March 17, 2019
Chemical and Biological Components of Urban Aerosols in Africa: Current Status and Knowledge GapsEgide Kalisa, Stephen Archer, Edward Nagato, et al.
Molecular Pharmacology|July 7, 2023
Differential Effects of Remdesivir and Lumacaftor on Homomeric and Heteromeric hERG ChannelsNoah Campagna, Erika Wall, Kevin Lee, et al.
European Journal of Pharmacology|June 8, 2011
The effects of gabapentin in two animal models of co-morbid anxiety and visceral hypersensitivitySiobhain M O' Mahony, Anne-Marie Coelho, Patrick Fitzgerald, et al.
Biorxiv : the Preprint Server for Biology|March 23, 2026
MORPHE: Bridging Image Generation and Spatial Omics for Tissue SynthesisYuan Feng, Zachary Robers, Leyla Rasheed, et al.
The Journal of Physiology|September 14, 2016
Development of a high-throughput method for real-time assessment of cellular metabolism in intact long skeletal muscle fibre bundlesRui Li, Frederik J Steyn, Michael B Stout, et al.
Journal of Vascular Surgery|September 4, 2017
Randomized clinical trial of negative pressure wound therapy for high-risk groin wounds in lower extremity revascularizationKevin Lee, Patrick B Murphy, Matthew V Ingves, et al.
Vascular Health and Risk Management|July 26, 2017
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapyVybhav Jetty, Charles J Glueck, Kevin Lee, et al.
Pageof 32